| Name | Title | Contact Details |
|---|---|---|
Chris Hodes |
Regional Sales Director | Profile |
Steve O'Brien |
SVP, Talent Acquisition | Profile |
Hillary Bochniak |
Chief Human Resources Officer | Profile |
Robyn Aycock |
Regional Sales Director-Southeast | Profile |
Stanford Rudnick |
Interim Chief Financial Officer and Chief Strategy Officer | Profile |
Mirum Pharmaceuticals (NASDAQ: MIRM) is dedicated to creating life-changing therapies for patients with liver diseases. We are advancing our lead product candidate for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) — conditions with a profound and devastating impact on quality of life for young patients and their families. Untreated, these conditions can lead to liver failure and inflict life-altering symptoms including stunted growth and severe, non-stop itching. Under current standard of care, patients often require a liver transplant and are at higher risk of many serious health issues. Working closely with patients and caregiver communities, we intimately understand the challenges of living with cholestatic liver diseases. Based on a wealth of data from clinical trials spanning multiple years and involving more than one hundred patients, we believe our approach can address the underlying cause of symptoms and liver damage. Our goal is to give families their lives back.
Amedra Pharmaceuticals is a Middlesex, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Physician Partner is a Newbury Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Dripping Springs Pharmacy is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.